Natera Chairman Matthew Rabinowitz Sells $16.4 Million in Shares

Natera Executive Chairman Matthew Rabinowitz sold $16.4 million of company common stock on September 11, 2026, while the firm's shares traded near their 52-week high. The transaction involved 50,000 shares and was executed through a pre-arranged trading plan.

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2026," noted the official SEC filing detailing the divestment.

Transaction Details

Mr. Rabinowitz offloaded the 50,000 shares at prices ranging from $325.0075 to $329.6247 per share, according to data from Investing.com. Following this sale, he retains a direct holding of 2,225,394 shares of Natera (NTRA) common stock.

As of September 15, 2026, Natera stock is trading at $348.84, near its 52-week peak of $343.18.

Understanding Rule 10b5-1 Plans

The sale was conducted under a Rule 10b5-1 trading plan, a mechanism that allows corporate insiders to establish a predetermined schedule for selling company equity. By setting these parameters in advance (in this case, on June 12, 2026), executives can execute trades at specific times or prices regardless of any material non-public information they might later possess. This structure provides an affirmative defense against potential allegations of insider trading.

Impact on Holdings

For investors monitoring insider activity, these plans provide transparency by separating the timing of the sale from the release of company-specific news. The $16.4 million divestment accounts for a fraction of Mr. Rabinowitz's total equity position in the genetic testing company. His remaining stake of over 2.2 million shares maintains his position in the firm.